Claims for Patent: 8,354,496

Summary for Patent: 8,354,496

Title:	Isoforms of brain natriuretic peptide
Abstract:	Methods and materials for diagnosing and treating heart conditions (e.g., heart failure) and kidney conditions (e.g., kidney failure) are described.
Inventor(s):	Pan; Shuchong (Rochester, MN), Simari; Robert D. (Rochester, MN)
Assignee:	Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	10/561,014
Patent Claims:	1. A purified natriuretic polypeptide comprising: (a) a first region comprising residues 1-27 of SEQ ID NO:16, or residues 1-27 of SEQ ID NO:16 with 1 to 5 substitutions, and (b) a second region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:1, wherein said polypeptide increases diuresis or natriuresis when administered to a mammal. 2. The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:1. 3. The purified natriuretic polypeptide of claim 1, wherein said first region comprises residues 1-27 of SEQ ID NO:16. 4. The purified natriuretic polypeptide of claim 1, wherein said first region comprises residues 1-27 of SEQ ID NO:16 with 1 to 5 substitutions. 5. The polypeptide of claim 1, wherein said second region comprises the amino acid sequence of SEQ ID NO:1. 6. The polypeptide of claim 1, wherein said second region consists of the amino acid sequence of SEQ ID NO:1. 7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified natriuretic polypeptide comprising (a) a first region comprising residues 1-27 of SEQ ID NO:16, or residues 1-27 of SEQ ID NO:16 with 1 to 5 substitutions, and (b) a second region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:1, wherein said polypeptide increases diuresis or natriuresis when administered to a mammal. 8. The pharmaceutical composition of claim 7, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:1. 9. The pharmaceutical composition of claim 7, wherein said pharmaceutically acceptable carrier is sterile water, sterile saline, a polyalkylene glycol, an oil of vegetable origin, a hydrogenated naphthalene, lactose, pregelatinized maize starch, polyvinylpyrrolidone, hydroxypropyl methylcellulose, microcrystalline cellulose, calcium hydrogen phosphate, magnesium stearate, talc, silica, potato starch, sodium starch glycolate, or sodium lauryl sulfate. 10. The pharmaceutical composition of claim 7, wherein said first region comprises residues 1-27 of SEQ ID NO:16. 11. The pharmaceutical composition of claim 7, wherein said first region comprises residues 1-27 of SEQ ID NO:16 with 1 to 5 substitutions. 12. The pharmaceutical composition of claim 7, wherein said second region comprises the amino acid sequence of SEQ ID NO:1. 13. The pharmaceutical composition of claim 7, wherein said second region consists of the amino acid sequence of SEQ ID NO:1. 14. A purified mature BNP2 polypeptide comprising the amino acid sequence of SEQ ID NO:36. 15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a mature BNP2 polypeptide comprising the amino acid sequence of SEQ ID NO:36.

Details for Patent 8,354,496

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2023-06-20